Keynote Lecture Series

Laboratory Workforce: Today & Tomorrow
September 22, 2019 9:15am - 10:15am
Panelists: Jim Flanigan, CAE, Executive Director, American Society for Clinical Laboratory Science; Edna Garcia, MPH, Director, Scientific Engagement and Research, American Society for Clinical Pathology; Sharon Kneebone, CAE, Executive Director, National Society for Histotechnology; Matt Schulze, Director, Center for Public Policy, American Society for Clinical Pathology
Moderator: Luis Chiriboga, PhD, HT(ASCP)QIHC, Research Assistant Professor, Department of Patholoyg, NYU Langone Health


Our workforce is aging, pressure is intensifying to do more with less, there is a shortage of clinical education sites, and the need to educate and influence via policy efforts has never been greater. Join our panel of experts from ASCLS, ASCP, an NSH who will share insights on the challenges facing laboratory staffing today in in the future.

Overall employment of medical laboratory technologists and technicians is expected to grow 13% from 2016 – 2026, faster than average for ALL occupations. An increase in the aging population is expected to lead to a greater need to diagnose medical conditions, such as cancer or type 2 diabetes, through laboratory procedures. 1  As retirement rates continue to increase the field needs to intensify its efforts on recruiting the next generation of laboratory personnel by enrolling more students in accredited training programs or getting more people involved in obtaining experience necessary to become certified. 2  
1 https://www.bls.gov/ooh/healthcare/medical-and-clinical-laboratory-technologists-and-technicians.htm#tab-1
2 Garcia, E., Kundu, I., Fong, K., The American Society for Clinical Pathology’s 2017 Wage Survey of Medical Laboratories in the United States, 22-23.


 

C.F.A. Culling Memorial Lecture: Teaching your body to fight cancer with gene-engineered T cell immunotherapy
September 23, 2019  9:15am – 10:15am
Presented by Laura Johnson, PhD, Senior Director, Head of Cell Therapy Clinical Biomarkers, Experimental Medicine Unit, GlaxoSmithKline, Collegeville PA


Gene-engineered T cell therapy takes the body’s natural ability to seek and destroy pathogens such as virus and bacteria, and redirects it to target cancer with the exquisite sensitivity of a tumor-specific antibody (Ab) or T cell receptor (TCR) while packing the punch of a cytotoxic T cell. The field of adoptive cell therapy for solid tumors was established with the discovery that tumor-infiltrating T lymphocytes could be expanded and used to treat and even cure patients with metastatic melanoma. Tumor-specific T-cell receptors (TCRs) were identified and engineered into patient peripheral blood T lymphocytes, which were also found to treat tumors. However, these were limited by patient HLA-restriction. Close behind came generation of chimeric antigen receptor (CAR) gene-engineered T cells, combining the exquisite recognition of an antibody with the effector function of a T cell. The advent of CD19-targeted CARs for treating patients with multiple forms of advanced B-cell malignancies met with great success, with up to 95% response rates. Applying CAR treatment to solid tumors, however, has just begun, but already certain factors have been made clear: the tumor target is of utmost importance for clinicians to do no harm; and solid tumors have additional challenges compared with hematologic ones. This talk will provide an overview of T cell immunotherapy, its successes, challenges, and future.  

C.F.A. Culling Memorial Lecture Sponsored by PolyScientific R&D

Back to Top